Simplex Trading, LLC I Mab Transaction History

Simplex Trading, LLC

$3.35 Billion
Q1 2024

A detailed history of Simplex Trading, LLC transactions in I Mab stock. As of the latest transaction made, Simplex Trading, LLC holds 84 shares of IMAB stock, worth $132. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 4 2000.0%

Holding current value

$132

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	BUY	$1.54 - $2.37 $123 - $189	80 Added 2000.0%	84 $0
Q4 2023 Feb 02, 2024	SELL	$1.21 - $1.9 $1,229 - $1,930	-1,016 Reduced 99.61%	4 $0
Q3 2023 Nov 01, 2023	SELL	$1.18 - $3.06 $661 - $1,716	-561 Reduced 35.48%	1,020 $1,000
Q2 2023 Aug 04, 2023	BUY	$2.95 - $3.85 $64 - $84	22 Added 1.41%	1,581 $4,000
Q1 2023 Apr 27, 2023	SELL	$3.08 - $7.39 $24,874 - $59,681	-8,076 Reduced 83.82%	1,559 $5,000

Q4 2022 Feb 02, 2023	BUY	$3.22 - $4.86 $27,006 - $40,760	8,387 Added 672.04%	9,635 $40,000
Q3 2022 Nov 04, 2022	BUY	$4.01 - $12.34 $5,004 - $15,400	1,248 New	1,248 $5,000
Q2 2022 Aug 03, 2022	SELL	$8.27 - $18.43 $14,083 - $31,386	-1,703 Closed	0 $0
Q1 2022 May 02, 2022	BUY	$12.54 - $46.93 $20,064 - $75,088	1,600 Added 1553.4%	1,703 $27,000
Q4 2021 Feb 23, 2022	SELL	$45.28 - $74.5 $7,335 - $12,069	-162 Reduced 61.13%	103 $4,000
Q3 2021 Oct 28, 2021	SELL	$57.18 - $84.43 $5,718 - $8,443	-100 Reduced 27.4%	265 $22,000
Q2 2021 Aug 12, 2021	BUY	$47.86 - $83.95 $7,896 - $13,851	165 Added 82.5%	365 $30,000
Q1 2021 Apr 26, 2021	BUY	$44.38 - $63.97 $8,876 - $12,794	200 New	200 $9,000

Others Institutions Holding IMAB

# of Institutions

Shares Held

16M

Call Options Held

11.9K

Put Options Held

3.5K

View Full List

About I-Mab

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $131M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

More about IMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Account

Simplex Trading, LLC I Mab Transaction History